Search Bar & Filters
Found 30 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating enfortumab vedotin in Indian adults with advanced or metastatic urothelial cancer, a type of bladder lining cancer that has spread. This study aims to confirm the safety of this treatment in this specific population. The trial is a phase 4, open-label, single-arm study focusing on adults who have previously received other cancer treatments including platinum-containing regimens and checkpoint inhibitors. Participants receive enfortumab vedotin via intravenous infusion on days 1, 8, and 15 of each 28-day cycle, with three infusions per cycle. The treatment is given slowly through a vein. All participants receive this drug as there is no comparison group. The study includes multiple cycles of treatment depending on participant response and tolerance. During the study, participants will visit the clinic several times for health checks, laboratory tests, vital sign monitoring, electrocardiograms, and assessments of their performance status. Researchers will measure adverse events, laboratory abnormalities, and response rates to treatment over periods ranging from 6.5 months to 34 months. Participants are also monitored for safety throughout the treatment and follow-up phases.
Actively Recruiting
The trial investigates treatments for adults with KRASNRAS and BRAF wild-type recurrent, unresectable, or metastatic colorectal cancer who have previously undergone chemotherapy. It compares how long participants live without disease progression and overall survival when treated with two different combinations of chemotherapy and targeted biological agents. This phase 3 study explores differences in outcomes between the use of amivantamab plus FOLFIRI chemotherapy and cetuximab or bevacizumab plus FOLFIRI chemotherapy. Participants are randomly assigned to one of two groups. One group receives amivantamab together with FOLFIRI, a chemotherapy regimen including 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan. The other group receives either cetuximab or bevacizumab with the same FOLFIRI chemotherapy. Treatments are given in 28-day cycles and continue until disease progression is observed on scans or other stopping criteria are met. During the study, participants undergo regular monitoring including radiographic scans to assess disease status and progression-free survival for up to 2 years and overall survival for over 4 years. Researchers also evaluate tumor response rates, duration and time to response, quality of life through questionnaires, side effects, and laboratory tests. The total study duration may extend up to more than 4 years to thoroughly assess treatment outcomes and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the drug baricitinib for treating Juvenile Idiopathic Arthritis JIA in children and adolescents aged 1 to less than 18 years. This Phase 3 study focuses on participants who have already taken part in previous baricitinib studies for JIA to understand long-term effects. Participants receive baricitinib orally as the study treatment. This is a single-group study, meaning all participants will take baricitinib without comparison to a placebo or other drugs. The study follows participants for up to 264 weeks about 5 years to monitor treatment effects and safety over a long period. During the study, researchers will track serious adverse events, any permanent stops of baricitinib, and various measures of disease activity, pain, and skin condition related to JIA. These include assessments like the Pediatric American College of Rheumatology response index and Juvenile Arthritis Disease Activity Score. Participants will be monitored regularly throughout the study to evaluate health and immune responses while taking the study drug.
Actively Recruiting
Researchers are studying the effects of elritercept TAK-226, KER-050 in treating anemia in adults with very low, low, or intermediate-risk myelodysplastic syndromes MDS who require regular blood transfusions. This Phase 3, randomized, double-blind, placebo-controlled trial aims to find out how well elritercept reduces the need for red blood cell RBC transfusions, especially over longer periods or in adults with high transfusion needs. The study also monitors the safety and tolerability of elritercept. Participants who qualify will be randomly assigned in a 21 ratio to receive either elritercept or a matching placebo by subcutaneous injection every 4 weeks. The study includes a Primary Phase lasting 24 weeks, followed by a Secondary Phase of an additional 24 weeks, during which the same blinded treatment continues. Study visits are scheduled every 2 weeks for the first 6 cycles and every 4 weeks thereafter. An Extension Phase allows eligible participants to continue treatment until they choose to stop or the study is unblinded. Throughout the study, participants will undergo regular assessments including MDS disease evaluations every 24 weeks, laboratory tests, vital sign monitoring, and safety follow-up visits every 4 weeks for 8 weeks after the last dose. Long-term follow-up will continue quarterly for up to 5 years to monitor ongoing health status. The main outcome measured is the percentage of participants achieving transfusion independence for at least 8 weeks during the first 24 weeks of treatment.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of clemizole hydrochloride EPX-100 as an additional treatment for children and adults with Dravet syndrome, a rare and severe form of epilepsy. This is a Phase 3, randomized, double-blind, placebo-controlled study conducted across multiple centers. The trial aims to assess whether clemizole HCl can help reduce the number of motor seizures experienced by participants whose seizures are not fully controlled by other anti-epileptic drugs AEDs. Participants will be randomly assigned to receive either clemizole HCl or a matching placebo twice daily during the double-blind phase, which includes a dose titration period followed by a maintenance period lasting up to 16 weeks. Those who complete this phase may have the option to join an open-label extension phase where they will receive clemizole HCl. The investigational treatments are given as oral solutions. Throughout the study, participants will be monitored for changes in the frequency of countable motor seizures over 28-day periods compared to their baseline seizure counts. Other assessments include seizure-free days, use of rescue AEDs, and clinician and caregiver evaluations of improvement. Safety will be closely followed by tracking adverse events. The overall participation may last up to 20 weeks or longer if the optional extension is chosen.
Actively Recruiting
Researchers are evaluating the efficacy and safety of orforglipron in adults with overweight who are at risk of developing obesity-related complications such as type 2 diabetes, hypertension, and dyslipidemia, or progressing to class 1 obesity. The study is a phase 3, randomized, double-blind, placebo-controlled trial that aims to understand whether this oral medication can reduce these risks over a two-year period. Participants will be randomly assigned to one of three groups receiving orforglipron orally throughout, orforglipron followed by placebo, or placebo followed by orforglipron. The study involves daily oral administration of these medications. The trial includes a long-term treatment period lasting up to 104 weeks about two years, during which participants are monitored for weight changes and the onset of obesity-related health issues. Throughout the study, participants will undergo regular assessments including measurements of body weight, waist circumference, blood pressure, blood markers like glycated hemoglobin and triglycerides, and quality of life questionnaires. Researchers will also monitor the time to onset of obesity-related complications and pharmacokinetics of orforglipron at specified intervals. Safety and effectiveness will be tracked continuously, with the primary outcome being the time until the development of obesity-related complications or progression to class 1 obesity.
Actively Recruiting
Researchers are evaluating elritercept compared with epoetin alfa to treat anemia in adults with lower-risk myelodysplastic syndromes LR-MDS who require regular red blood cell transfusions. The study focuses on how well elritercept reduces the need for transfusions, improves hemoglobin blood levels, and affects tiredness and quality of life. It also monitors the safety of elritercept and its impact on the disease in bone marrow and other body areas. Participants will be randomly assigned to receive either elritercept or epoetin alfa. Elritercept is given as a subcutaneous injection starting at 3.75 mgkg once every 4 weeks, with possible dose increases to 5.0 mgkg if needed. Epoetin alfa is given as a subcutaneous injection starting at 450 IUkg once weekly, with potential dose escalation up to 1050 IUkg maximum 80,000 IU. Treatment cycles last 28 days, and dosing continues throughout the study. During the study, participants will have regular assessments including blood tests to measure hemoglobin levels and transfusion requirements. Researchers will track fatigue and quality of life using specific questionnaires. Safety will be closely monitored, including side effects and changes in disease status. The main outcome is the proportion of participants who become independent of red blood cell transfusions for at least 12 consecutive weeks while having improved hemoglobin. The study may last up to approximately 5 years from the first dose to end of treatment.
Actively Recruiting
Researchers are evaluating remibrutinib for its effectiveness and safety in treating patients with secondary progressive multiple sclerosis SPMS. This Phase III, randomized, double-blind, placebo-controlled study involves about 1275 participants who meet specific criteria, including an SPMS diagnosis and disability progression. The trial is designed to provide detailed data on remibrutinibs impact compared to placebo, with a focus on disability progression and other neurological measures. Participants are randomly assigned to receive either remibrutinib or a matching placebo tablet during the Core Part of the study, which is event-driven and double-blind. Following this, there is an Extension Part where all participants receive open-label remibrutinib tablets. Treatment is oral and involves ongoing monitoring to assess long-term effects and safety. Throughout the study, participants will undergo regular assessments including disability evaluations using the Expanded Disability Status Scale EDSS, Timed 25-Foot Walk, 9-Hole Peg Test, and cognitive testing with the Symbol Digit Modalities Test SDMT. Brain imaging will be used to track lesion development and brain atrophy. Safety will be closely monitored by recording adverse events. The total participation may span up to approximately five years, covering both core and extension phases.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a single dose of RABI-767 administered by endoscopic ultrasound EUS guided peripancreatic injection in adults with predicted severe acute pancreatitis. This phase 2a clinical trial compares RABI-767 plus supportive care to supportive care alone to better understand if this treatment is safe and beneficial. The study is sponsored by Panafina, Inc. and focuses on adults aged 18 to 85 years with specific imaging and clinical criteria. Participants are randomly assigned to receive either a single 125 mg dose of RABI-767 by EUS-guided injection alongside standard care or standard care alone without the investigational drug. The trial uses a parallel design to compare these two groups. The single-dose RABI-767 administration occurs early in the treatment phase, with follow-up assessments extending up to 60 days after dosing. Throughout the study, participants will be monitored closely for adverse events and changes in clinical chemistry, hematology, vital signs, oxygen measurements, and pancreatitis severity scores. Imaging studies such as contrast-enhanced CT or MRI will assess pancreatic changes. Researchers will track hospital stay duration, intensive care use, and rehospitalizations. Safety and efficacy outcomes are collected up to 60 days following treatment, with the overall participation lasting several weeks to months depending on individual recovery and follow-up timing.
Actively Recruiting
Researchers are conducting an 18-month Phase 3 clinical trial to study the safety and efficacy of oral nizubaglustat AZ-3102 in children and young people aged 4 years and older with late-infantile and juvenile forms of Niemann-Pick Type C NPC disease. This randomized, double-blind, placebo-controlled study aims to compare the effects of nizubaglustat against placebo on ataxic symptoms and other disease manifestations in this rare neurological condition. Participants will receive once-daily oral dispersible tablets of either nizubaglustat or a matching placebo over 18 months. The study examines the drugs pharmacokinetics and pharmacodynamics, along with its safety and tolerability. The trial is conducted at multiple centers and includes a parallel study design where participants are randomly assigned to one of the two groups. Throughout the study, participants will undergo regular assessments including the Scale for the Assessment and Rating of Ataxia SARA, Vineland Adaptive Behavior Scale, Penetration-Aspiration Scale, and several other evaluations at baseline and at months 6, 12, and 18. Researchers will also monitor seizure frequency and drug plasma levels, as well as record any adverse effects. The primary outcomes focus on changes in ataxia scores over the 18-month period to evaluate the treatments impact.
1-10 of 30
1